Trial failure prompts soul-searching for critical-care specialists


In late May, researchers delivered the final analysis of the boldly named PROWESSSHOCK trial. Despite the study’s gallant moniker, though, the antisepsis drug Xigris (activated protein C) showed little prowess— and the results came as no shock, as Eli Lilly, the Indiana-based drugmaker behind the medicine, had already withdrawn Xigris from worldwide markets… (More)
DOI: 10.1038/nm0712-1000


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics